The study aims to evaluate the efficacy of [64Cu]Cu-DOTA-TYPE7 as a PET radiotracer for imaging EphA2-expressing tumors.
Development and evaluation of [64Cu]Cu-DOTA-TYPE7 as a PET imaging agent.
Focused on EphA2-expressing disease models.
Assessed imaging capabilities through preclinical trials.
Demonstrated effective targeting of EphA2-expressing tumors using the radiotracer.
Provided foundational data for further development of EphA2-targeted treatments.
Abstract
Cu]Cu-DOTA-TYPE7 as a promising PET tracer for imaging EphA2-expressing diseases and provides a foundation for future development of EphA2-targeted theranostic applications.